-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Hengrui's innovative drug carrelizumab combined with familtinib first-line treatment of tumor cells PD-L1 expression positive [tumor proportion score (TPS) ≥1%] and not accompanied by EGFR/ALK gene abnormalities of recurrent or metastatic non-small cell lung cancer was proposed to be included in the list of breakthrough therapy varieties by the Center for Drug Evaluation of the National Medical Products Administration
.
At present, Hengrui Pharmaceutical is conducting a randomized, open-label, controlled, multicenter phase III clinical study
of carrelizumab combined with fametinib malate versus pembrolizumab in the first-line treatment of recurrent or metastatic non-small cell lung cancer with positive PD-L1 expression.
Fametinib malate capsules are small molecule multi-target tyrosine kinase inhibitors independently developed by Hengrui, which have inhibitory activity against a variety of receptor tyrosine kinases and belong to multi-target anti-angiogenic targeted drugs
.
PD-1 "sold the crown" into medical insurance, and the growth rate slowed down
PD-1 "sold the crown" into medical insurance, and the growth rate slowed down Since the first domestic PD-1 was approved for marketing in December 2018, just over 3 years before and after, the PD-1 market has ushered in more than ten products, as the third PD-1 inhibitor approved for marketing in China, the carrelizumab market performed well, and it jumped to the highest sales PD-1 product in 2020 in the second year of listing, and later came to the top
.
In 2021, the sales volume of single products in the hospital will reach nearly 1.
5 billion yuan, a year-on-year increase of 114%.
In-hospital sales of carrelizumab
In H1 2022, carrelizumab still holds the position
of PD-1 drug "sales champion".
However, compared with the 400% growth rate of tirelizumab, the growth rate of 16% of carrelizumab is obviously insufficient
.
In the first half of 2022, PD-1 drugs will be sold in the top 10 varieties in hospitals
Screenshot source: Yaorong Cloud National Hospital Sales Database
On the reason, in 2019, medical insurance intervened, and the domestic PD-1 price gradually "popularized" in three years, and Karelizhu bore the brunt
.
Before entering the national medical insurance in 2021, the price of carrelizumab with a specification of 200mg was 19,800 yuan / bottle, which was the most expensive of all domestic PD-1 drugs and was the performance pillar of Hengrui's innovative drug sector; After winning the bid, the price of carrelizumab plummeted to 2928 yuan / bottle, a drop of up to 85%.
Although the sales volume of carrelizumab increased by 361% year-on-year after winning the bid, the price of its "fracture" made Hengrui Pharmaceutical's anti-tumor business revenue in 2021 decrease by 14.
39%
year-on-year.
Since ancient times, innovation has been tortuous, and the horizontal layout has found a way out
Since ancient times, innovation has been tortuous, and the horizontal layout has found a way out Since its launch in May 2019, it has been approved for 8 indications in five major tumors, including lung cancer, liver cancer, esophageal cancer, nasopharyngeal cancer and lymphoma, of which 2 are first-line treatments for NSCLC, which is one of the leading domestic PD-1 products with the largest number of
approved indications and covered tumors.
However, in the context of the current PD-1 track involution, in addition to cooperating with the US pharmaceutical company Incyte (terminated in February 2018) and South Korea's CrystalGenomics (CG), Hengrui is also actively deploying the indications
of Carrelizab.
According to Hengrui's 2022 mid-year report, carerelizumab has also deployed a number of cancers such as breast cancer, cervical cancer, and solid tumors, and as many as 10 indications have been in the phase III clinical stage
.
Subsequent major clinical development pipeline of carrelizumab
Screenshot source: corporate financial report
